The β-lactamase cycle: a tale of selective pressure and bacterial ingenuity
A Matagne, A Dubus, M Galleni, JM Frère - Natural product reports, 1999 - pubs.rsc.org
The β-lactamase cycle: a tale of selective pressure and bacterial ingenuity - Natural Product
Reports (RSC Publishing) DOI:10.1039/A705983C Royal Society of Chemistry View PDF …
Reports (RSC Publishing) DOI:10.1039/A705983C Royal Society of Chemistry View PDF …
β-lactamases and β-lactamase inhibitors
JD Williams - International journal of antimicrobial agents, 1999 - Elsevier
Penicillin, the first of the β-lactam antibiotics, was introduced into medical practice in the
1940s. Since then, a large number of different β-lactams, including penicillins …
1940s. Since then, a large number of different β-lactams, including penicillins …
Class D β-lactamases: a reappraisal after five decades
DA Leonard, RA Bonomo… - Accounts of chemical …, 2013 - ACS Publications
Despite 70 years of clinical use, β-lactam antibiotics still remain at the forefront of
antimicrobial chemotherapy. The major challenge to these life-saving therapeutics is the …
antimicrobial chemotherapy. The major challenge to these life-saving therapeutics is the …
The growing genetic and functional diversity of extended spectrum beta‐lactamases
The β‐lactams—a large class of diverse compounds—due to their excellent safety profile
and broad antimicrobial spectrum are considered to be the most widely used therapeutic …
and broad antimicrobial spectrum are considered to be the most widely used therapeutic …
Avibactam and inhibitor-resistant SHV β-lactamases
ML Winkler, KM Papp-Wallace… - Antimicrobial agents …, 2015 - Am Soc Microbiol
ABSTRACT β-Lactamase enzymes (EC 3.5. 2.6) are a significant threat to the continued use
of β-lactam antibiotics to treat infections. A novel non-β-lactam β-lactamase inhibitor with …
of β-lactam antibiotics to treat infections. A novel non-β-lactam β-lactamase inhibitor with …
Extended-spectrum β-lactamases: a challenge for clinical microbiologists and infection control specialists
R Colodner - American journal of infection control, 2005 - Elsevier
Since first reported in Europe in the early 1980s, extended-spectrum β-lactamases (ESBLs)
have spread worldwide. When producing these broad-spectrum plasmid-encoded enzymes …
have spread worldwide. When producing these broad-spectrum plasmid-encoded enzymes …
ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii
TF Durand-Réville, S Guler, J Comita-Prevoir… - Nature …, 2017 - nature.com
Multidrug-resistant (MDR) bacterial infections are a serious threat to public health. Among
the most alarming resistance trends is the rapid rise in the number and diversity of β …
the most alarming resistance trends is the rapid rise in the number and diversity of β …
Editorial response: extended-spectrum β-lactamases: a call for improved detection and control
DL Paterson, VL Yu - Clinical Infectious Diseases, 1999 - academic.oup.com
Extended-spectrum b-lactamases (ESBLs) are enzymes produced by gram-negative bacilli
that have the ability to inactivate b-lactam antibiotics containing an oxyimino group (ie …
that have the ability to inactivate b-lactam antibiotics containing an oxyimino group (ie …
New drugs for multidrug-resistant gram-negative organisms: time for stewardship
A gradual rise in drug-resistant trends among Gram-negative organisms, especially
carbapenem-resistant (CR) Enterobacteriaceae (CRE), CR-Pseudomonas aeruginosa, and …
carbapenem-resistant (CR) Enterobacteriaceae (CRE), CR-Pseudomonas aeruginosa, and …
Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa …
SD Lahiri, S Mangani, T Durand-Reville… - Antimicrobial agents …, 2013 - Am Soc Microbiol
Although β-lactams have been the most effective class of antibacterial agents used in
clinical practice for the past half century, their effectiveness on Gram-negative bacteria has …
clinical practice for the past half century, their effectiveness on Gram-negative bacteria has …